FIELD: chemistry.
SUBSTANCE: invention relates to novel compounds of formula I or a pharmaceutically acceptable salt thereof, which possess properties of TOLL-like receptor (TLR9) inhibitor and can be used for treating autoimmune diseases, mediated by TLR9 activity. Diseases can be selected from cutaneous and systemic lupus erythematosus, insulin-dependent diabetes mellitus, rheumatoid arthritis, multiple sclerosis, atherosclerosis, psoriasis, psoriatic arthritis, inflammatory bowel disease, ankylosing spondylitis, autoimmune hemolytic anemia, Behget's syndrome, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome, Hashimoto's thyroiditis, idiopathic thrombocytopenia, myasthenia gravis, pernicious anemia, polyarteritis nodosa, polymyositis/dermatomyositis, primary biliary sclerosis, sarcoidosis, sclerosing cholangitis, Sjogren's syndrome, systemic sclerosis (scleroderma and CREST syndrome), Takayasu's arteritis, temporal arteritis, and Wegener's granulomatosis. In Formula I
X is absent or denotes aryl; Q is H, (CH2)qNR1R2, SR1 or CR1R2R2', where q is equal to 0 or 1; R1, R2 and R2', each independently, represent hydrogen, C1-C12 alkyl, or R1 and R2 together with a nitrogen atom, with which they are bonded form a 6-member heterocycle, containing two nitrogen atoms or a nitrogen atom and an oxygen atom, which can be optionally substituted with (C1-C4)alkyl or (CH2)pORa, where p is equal to 2-4; R7 is NR3R4; R3 and R4, each independently represent (C1-C12)alkyl, or R3 and R4, together with a nitrogen atom with which they are bonded, form or 6-member heterocycle containing 1-2 heteroatoms selected from a group consisting of O and N, and which can be optionally substituted with (C1-C4)alkyl; Y is NR11, where R11 is hydrogen or (C1-C12)alkyl; L is an alkyl or alkenyl, each containing from 2 to 10 carbon atoms; R5 is hydrogen, halogen, CF3, ORa, SRa, NRbRc or NH(CH2)pNRbRc; R6 is a halogen, (C1-C12)alkyl, CF3, phenyl, phenyl substituted with halogen, CN or CF3, or NH(CH2)pNRbRc; in each case Ra independently represents hydrogen, (C1-C6)alkyl; and said Rb and Rc, together with a nitrogen atom with which they are bonded, optionally form 5-6-member heterocycle, containing 1-2 heteroatoms selected from O and N, where heterocycle is optionally substituted with (C1-C4)alkyl; provided that if R5 and R6 denote H or methyl, then Q is not H.
EFFECT: obtaining novel compounds of formula.
19 cl, 5 tbl, 73 ex
Title | Year | Author | Number |
---|---|---|---|
TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2019 |
|
RU2815647C2 |
OBESITY TREATMENT | 2019 |
|
RU2822679C2 |
MACROCYCLIC SERINE PROTEASE INHIBITORS | 2009 |
|
RU2490272C2 |
IMIDAZOQUINOLINE SUBSTITUTED PHOSPHORIC ACID ESTER AS AGONIST, ITS PREPARATION AND USE | 2020 |
|
RU2812182C1 |
NOVEL CYCLOSPORIN DERIVATIVES FOR TREATMENT AND PREVENTION OF VIRAL INFECTIONS | 2011 |
|
RU2601742C2 |
BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR TREATING CANCER | 2015 |
|
RU2741914C2 |
5,5-CONDENSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | 2010 |
|
RU2554087C2 |
NEW SUBSTITUTED 8-HETEROARYLXANTINES AND BASED PHARMACEUTICAL COMPOSITION | 2004 |
|
RU2357969C2 |
N4-PHENYLQUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS RECEPTOR TYROSINE KINASE TYPE ERBB INIHIBITORS FOR TREATING HYPERPROLIFERATIVE DISEASES | 2006 |
|
RU2428421C2 |
MONOMER DERIVATIVES OF GLYCOPEPTIDE ANTIBIOTIC | 2005 |
|
RU2424248C2 |
Authors
Dates
2017-01-10—Published
2012-06-01—Filed